Revvity, Inc. · RVTY · Next earnings

Revvity, Inc. reports Monday, Feb 1, 2027

RVTY reports before market open with consensus EPS at $1.62 and revenue at $759.8M. Last quarter: Revvity raises FY2026 outlook after 7% organic Q3 growth

Reports Before market open88 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $1.62 Calendar consensus
Consensus revenue $759.8M Calendar consensus
Report date Feb 1, 2027 Monday, date estimated
Session Before market open 88 days away

Where RVTY left off: FY2026 Q3

Full report

Revvity raises FY2026 outlook after 7% organic Q3 growth

EPS surprise +6.2% Reported $1.38 vs $1.30
Revenue surprise +4.9% Reported $728.9M vs $694.7M
Stock move +7.8% Event window
Subsequent drift 0.0% Up to 20 sessions

Management raised FY2026 organic growth guidance from 4–5% to 5% and adjusted EPS guidance from $5.30–$5.40 to $5.40–$5.45. It also noted that Q4 organic growth guidance steps down relative to Q3; the supplied analysis does not quantify that step-down.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Bulk reagent orders and order timing may not recur at the same level, and the contribution of bulk orders to quarterly results remains a question.
  • Q4 organic growth guidance steps down relative to Q3, with timing of instrument and backlog conversion affecting quarterly results.
  • Management described AI demand as early-stage; it could moderate, particularly in software growth.
  • Reproductive-health market pressures in APAC and execution of the China immunodiagnostics divestiture remain risks.
  • The ACD/Labs integration and continued capacity expansion require execution.

Questions analysts left open

  • How much bulk reagent orders contributed to Q3 and whether that contribution is sustainable.
  • Backlog levels and capacity to meet high-content screening demand.
  • Why Q4 organic growth guidance steps down relative to Q3.
  • How much revenue is exposed to AI-related demand.
  • Outlook for reproductive health and immunodiagnostics.

Ask FN2 about RVTY next report

Transcript, numbers and history already loaded
What should I watch for in RVTY's next earnings report?How did RVTY guide last quarter, and is consensus above or below that?Give me the bull and bear case going into RVTY earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the RVTY recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent RVTY quarters

All RVTY earnings
+7.8%FY2026 Q3-3.3%FY2026 Q2+6.7%FY2026 Q1-1.6%FY2025 Q4

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q3

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.